Thermo Fisher Scientific Idarucizumab Humanized Recombinant Human Monoclonal Antibody

Applications

Tested Dilution

Publications

ELISA (ELISA)

Assay-dependent

-

Product Specifications

Species Reactivity

Chemical

Host/Isotype

Human / IgG1, F(ab), kappa

Expression System

CHO cells

Class

Recombinant Monoclonal

Type

Antibody

Immunogen

Pradaxa (Dabigatran Etexilate Mesylate) dabigatran etexilate mesylate

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

2.53 mg/mL

Purification

Protein L

Storage buffer

30mM histidine, pH 5.8, with 10% sucrose, 0.06% Tween 80

Contains

no preservative

Storage conditions

-20° C, Avoid Freeze/Thaw Cycles

Shipping conditions

Ambient (domestic); Wet ice (international)

RRID

AB_2911141

Product Specific Information

Endotoxin level < 0.01EU/µg by LAL method

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 °C for one week. Store at -20 to -80 °C for twelve months from the date of receipt.

Target Information

Idarucizumab is a humanized monoclonal antibody fragment (Fab) derived from an immunoglobulin G1 isotype molecule that binds to and inactivates the oral anticoagulant dabigatran, thereby reversing its anticoagulant effect. As a direct acting oral anticoagulant (DOAC), one of the risks associated with the use of dabigatran includes bleeding, especially when given to patients at increased risk (elderly, chronic kidney disease, concomitant NSAID or warfarin use, etc.). Approved under the tradename Praxbind (FDA), idarucizumab is indicated for the emergency treatment of dabigatran-associated bleeding in life-threatening or surgically induced situations. Its use is associated with immediate, complete and sustained reversal of the anticoagulant effects of dabigatran. Idarucizumab protein structure can be viewed below, with disulfide bridges at the following points: H22-H95, H149-H205, H225-L-219, L23-L93, L139-L199.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.